Meine Merkliste  

2.463 Aktuelle Fachpublikationen von Future Medicine


Transcriptional response to vancomycin in a highly vancomycin-resistant Streptomyces coelicolor mutant

24.06.2014 | Fernando Santos-Beneit; Lorena T Fernández-Martínez; Antonio Rodríguez García; Seomara Martín-Martín; María Ordóñez- ..., Future Microbiology, 2014

ABSTRACT:  Aim: The main objective of this study is to understand the mechanism of vancomycin resistance in a Streptomyces coelicolor disrupted mutant highly resistant to vancomycin. Materials & methods: Different techniques have been performed in the study including gene disruption, primer ...


Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms

24.06.2014 | Anuradha Chowdhary; Cheshta Sharma; Ferry Hagen; Jacques F Meis, Future Microbiology, 2014

ABSTRACT:  Aspergillus fumigatus, a ubiquitously distributed opportunistic pathogen, is the global leading cause of aspergillosis. Azole antifungals play an important role in the management of aspergillosis. However, over a decade, azole resistance in A. fumigatus isolates has been increasingly ...


Using MLST to study bacterial variation: prospects in the genomic era

24.06.2014 | Keith A Jolley; Martin CJ Maiden, Future Microbiology, 2014

ABSTRACT:  Multilocus sequence typing (MLST) indexes the sequence variation present in a small number (usually seven) of housekeeping gene fragments located around the bacterial genome. Unique alleles at these loci are assigned arbitrary integer identifiers, which effectively summarizes the ...


Highlights from the latest articles in pharmacogenomics of solid organ transplantation

23.06.2014 | Andrzej Pawlik; Ewa Dabrowska-Zamojcin; Violetta Dziedziejko, Pharmacogenomics, 2014

Pharmacogenomics May 2014, Vol. 15, No. 7, Pages 905-907.


Warfarin dose requirements in a patient with the CYP2C9*14 allele

23.06.2014 | Yee Ming Lee; Jessica Eggen; Vinay Soni; Katarzyna Drozda; Edith A Nutescu; Larisa H Cavallari, Pharmacogenomics, 2014

We describe a 64-year-old male of Indian descent with a history of atrial fibrillation who was started on warfarin after hospital admission for acute stroke. He received genotype-guided warfarin dosing as per the standard-of-care at our hospital, with daily dose recommendations provided by the ...


Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins

23.06.2014 | Aizati NA Daud; Jorieke EH Bergman; Marian K Bakker; Hao Wang; Hermien EK de Walle; Torsten Plösch; Bob Wilffert, Pharmacogenomics, 2014

One of the ongoing issues in perinatal medicine is the risk of birth defects associated with maternal drug use. The teratogenic effect of a drug depends, apart from other factors, on the exposition of the fetus to the drug. Transporter proteins are known to be involved in the pharmacokinetics of ...


Assessment of CYP450 genetic variability effect on methadone dose and tolerance

23.06.2014 | Hui-Ju Tsai; Sheng-Chang Wang; Sheng-Wen Liu; Ing-Kang Ho; Yao-Sheng Chang; Yu-Ting Tsai; Keh-Ming Lin; Yu-Li Liu, Pharmacogenomics, 2014

Aim: Methadone dose is related to treatment success in individuals under methadone maintenance treatment (MMT). We constructed a gene matrix using previously identified genetic polymorphisms in CYP450 and determined their genetic influence on methadone dose or tolerance. Materials & methods: The ...


Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment

23.06.2014 | Juan Jose Cerezo-Manchado; Vanessa Roldan; Mario Rosafalco; Ana Isabel Anton; Ana Belen Arroyo; Nuria Garcia-Barbera ..., Pharmacogenomics, 2014

Aim: To analyze VKORC1, CYP2C9 and CYP4F2 polymorphisms in relation to the main outcomes in the first stages of acenocoumarol therapy. Patients & methods: Nine hundred and forty one patients who had started therapy and in whom time to stable dosage, time to over-anticoagulation and adverse events ...


Pharmacogenomics of methadone maintenance treatment

23.06.2014 | Andrew A Somogyi; Daniel T Barratt; Robert L Ali; Janet K Coller, Pharmacogenomics, 2014

Methadone is the major opioid substitution therapy for opioid dependence. Dosage is highly variable and is often controlled by the patient and prescriber according to local and national policy and guidelines. Nevertheless many genetic factors have been investigated including those affecting its ...


Clopidogrel dose adjustment after outpatient screening for CYP2C19 variant alleles: a pilot study

23.06.2014 | Joseph S Rossi; Michael Cammarata; Jayalalitha Dharmavaram; Karen Weck; Christine Walko; Don Gabriel; Jack Kuritzky; ..., Pharmacogenomics, 2014

This pilot study examined the feasibility of outpatient screening and clopidogrel dose adjustment for patients with previous percutaneous coronary intervention and at least one CYP2C19 loss-of-function allele. After screening a total of 211 outpatients, 50 patients were enrolled in a crossover ...


Seite 2 von 247
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.